With the increasing use of antiplatelet agents (APA), their management during the perendoscopic period has become a more common and more difficult problem. The increase in use is due to the availability of new drugs and the widespread use of drug-eluting coronary stents. Acute coronary syndromes can occur when APA therapy is withheld for noncardiovascular interventions. Guidelines about APA management during the perendoscopic period are traditionally based on assessments of the procedure-related risk of bleeding and the risk of thrombosis if APA are stopped. New data allow better assessment of these risks, of the necessary duration of APA discontinuation before endoscopy, of the use of alternative procedures (mostly for endoscopic retrograde cholangiopancreatography [ERCP]), and of endoscopic methods that can be used to prevent bleeding (following colonic polypectomy). This guideline makes graded, evidence-based, recommendations for the management of APA for all currently performed endoscopic procedures. A short summary and two Tables are included for quick reference.

1. Introduction ▼

Antiplatelet agents (APA) reduce the aggregation of platelets and are commonly used in patients with coronary heart disease, peripheral arteriopathy, and cardiac arrhythmias. Coronary heart disease represents the most frequent indication because there is a risk of coronary stent occlusion which requires continuous treatment with APA. The risk of stent occlusion is most important in the immediate post-stent placement period. There are varying levels of thrombotic risk depending on the type of stent placed (bare or drug-eluting stent) as well as other risk factors [1]. Conditions that require APA therapy as well as the modalities of APA administration have recently been updated in guidelines issued by the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery [2].

The discontinuation of APA therapy in patients undergoing a noncardiovascular intervention accounts for approximately 5% of hospitalizations for acute coronary syndrome. Therefore, perendoscopic management of patients with a high thrombotic risk if APA is stopped requires knowledge of both the bleeding risk associated with endoscopic procedures and the potential risks associated with discontinuation of APA therapy [3].

In this Guideline, the current evidence is reviewed and recommendations made for the management of APA therapy in patients undergoing endoscopic procedures.

2. Methods ▼

The European Society of Gastrointestinal Endoscopy (ESGE) commissioned and funded this Guideline, which was based on preparatory work performed by the French Society of Digestive Endoscopy. The process was similar to that used in creating other ESGE guidelines [4]. It included face-to-face meetings, teleconferences, and electronic-based discussions among subgroups and members of the entire committee during 2010. Subgroups were formed, each of which was charged with a series of clearly defined key questions (see Appendix e1, available online). The committee chair worked with subgroup leaders to identify pertinent search terms (see Appendix e2, available online). Searches of Medline (via Pubmed), the Cochrane Library, Embase, and the internet were performed. Articles were first selected by title; their relevance was then confirmed by review of the corresponding abstract. Publications with content that was considered irrelevant were excluded. Additional articles were identified...
Table 1  Definitions of categories for evidence levels and recommendation grades used in this Guideline [5].

<table>
<thead>
<tr>
<th>Evidence level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1+</td>
<td>High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias</td>
</tr>
<tr>
<td>1+</td>
<td>Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias</td>
</tr>
<tr>
<td>1–</td>
<td>Meta-analyses, systematic reviews, or RCTs with a high risk of bias</td>
</tr>
<tr>
<td>2+</td>
<td>High quality systematic reviews of case–control or cohort studies; high quality case–control studies or cohort studies with a very low risk of confounding, bias, or chance, and a high probability that the relationship is causal</td>
</tr>
<tr>
<td>2+</td>
<td>Well conducted case–control or cohort studies with a low risk of confounding, bias, or chance, and a moderate probability that the relationship is causal</td>
</tr>
<tr>
<td>2–</td>
<td>Case–control or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship is not causal</td>
</tr>
<tr>
<td>3</td>
<td>Nonanalytic studies, e.g. case reports, case series</td>
</tr>
<tr>
<td>4</td>
<td>Expert opinion</td>
</tr>
</tbody>
</table>

Recommendation grades

A  At least one meta-analysis, systematic review, or RCT rated as 1++ and directly applicable to the target population or a systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results

B  A body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating overall consistency of results or extrapolated evidence from studies rated as 1++ or 1+

C  A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results or extrapolated evidence from studies rated as 2+

D  Evidence level 3 or 4 or extrapolated evidence from studies rated as 2++

RCT, randomized controlled trial.

by manually searching the reference lists of retrieved papers. A central repository of selected literature was made available to all members of the guideline development group. Evidence tables were generated for each key question based on meta-analyses or randomized controlled trials (RCTs) if these were available; otherwise, case–control studies, retrospective analyses, and case series were included. The number of articles retrieved and selected for each task force is indicated in the Evidence table (see Appendix e3, available online).

For important outcomes, articles were individually assessed by using the Method for Evaluating Research and Guideline Evidence (MERGE) checklists as amended by the Scottish Intercollegiate Guidelines Network [5]. Evidence levels and recommendation grades used in these guidelines were those recommended by the amended Scottish Intercollegiate Guidelines Network (Table 1) [5].

Subgroups agreed electronically on draft proposals that were presented to the entire group for general discussion during a meeting held in 2010 at the 18th United European Gastroenterology Week in Barcelona, Spain. During the meeting and following discussion, competing proposals for wording of recommendations or assigning strength of evidence were resolved by formal voting. When the Guideline development group was unable to reach a unanimous recommendation, the difference of opinion was formally recorded and the reasons for dissent were noted. The results of that discussion were incorporated into the subsequent Guideline version and again discussed using electronic mail. Literature searches were repeated in October 2010. Studies that were published after this date were not considered for inclusion. This time-point should be the starting point for literature searches when this Guideline is updated.

The manuscript was edited for style by the corresponding author, with approval by subgroup leaders and then by all members of the Guideline development group. In November 2010 the final draft was sent to all individual ESGE members. After incorporation of comments made by the individual ESGE members, the ESGE Governing Board endorsed the manuscript. It was sent to the Editorial Board of the journal Endoscopy. It underwent international peer review and all members of the Guideline development group approved the final version.

Evidence statements and recommendations are stated in italics; key evidence statements and recommendations are in bold. This Guideline was issued in 2011 and will be considered for review in 2014, or sooner if substantially different evidence becomes available. Any updates to the Guideline in the interim period will be noted on the ESGE website: http://www.esge.com/esge-guidelines.html.

3. Summary of statements and recommendations

Antiplatelet agents

Low doses of aspirin and thienopyridines (clopidogrel and prasugrel) irreversibly inhibit platelet aggregation. The minimal durations of APA discontinuation that allow for restoration of normal platelet aggregability are 5 days for aspirin/clopidogrel and 7 days for prasugrel.

APA management during the periendoscopic period balances the estimated risk of bleeding associated with the intended procedure and the risk of a thrombotic event when APA are withheld. The risks of bleeding associated with the most commonly performed endoscopic procedures are discussed in the following paragraphs. A summary of general and specific recommendations for the management of APA therapy during the periendoscopic period is presented in Table 2 and 3.

Standard diagnostic endoscopy with or without performance of mucosal biopsy

Esophagogastroduodenoscopy (EGD), colonoscopy, push enteroscopy and endoscopic ultrasonography (EUS) without fine-needle aspiration (FNA) present a minimal bleeding risk (Evidence level 2++). Mucosal biopsy sampling at any digestive site is associated with a very low bleeding risk that is not increased in patients taking APA (aspirin or clopidogrel) (Evidence level 2+). Prasugrel is likely to confer a low bleeding risk similar to that of clopidogrel in diagnostic endoscopic procedures (Evidence level 4).

For the diagnostic endoscopic procedures listed above without biopsy sampling, it is recommended to continue all APA treatment (Recommendation grade B). If biopsy sampling is indicated in patients taking single APA therapy of aspirin or clopidogrel, we recommend continuing APA therapy (Recommendation grade C). In patients taking a combination of aspirin and thienopyridines, we recommend continuing dual APA therapy if mucosal biopsies without electrocautery are anticipated (Recommendation grade D). For small-caliber EGD, the transoral rather than the transnasal route should be considered in patients receiving dual APA therapy (Recommendation grade D).
Resection of colon polyps

Post-polypectomy bleeding (PPB) is more frequent with the use of pure-cutting current as compared with blended or coagulation current. (Evidence level 2+). Definite risk factors for PPB include age > 65 years, anticoagulation, cardiovascular disease, polyp size ≥ 1 cm (Evidence level 2+). Aspirin does not increase the risk of PPB, irrespective of polyp size (Evidence level 2+). In patients taking clopidogrel, resection of small polyps (< 1 cm) is probably safe in patients taking clopidogrel (not prasugrel) with such preventive measures; insufficient data are available concerning prophylactic endoclip placement.

Endoscopic interventions that are effective in preventing PPB include placement of a detachable loop ligating device for large pedunculated polyps and submucosal injection of diluted adrenaline for sessile polyps. Efficacy of other measures, including endoclip placement, injection of saline and argon plasma coagulation, has not been definitively demonstrated (Evidence level 1+).

For polypectomy, it is recommended that pure-cutting current is not used (Recommendation grade C). It is also recommended that aspirin is not discontinued irrespective of polyp size (Recommendation grade B), and that thienopyridines are withheld if polyps > 1 cm have to be resected, provided that the patient is not at high risk for thrombotic events (Recommendation grade C). When polyps must be resected in patients who cannot discontinue thienopyridines, preventive measures (preferably detachable loop ligating device for pedunculated polyps, and sub-

Table 2 Management of antiplatelet agent therapy during the periendoscopic period.

<table>
<thead>
<tr>
<th>Bleeding risk</th>
<th>Continuation of aspirin?</th>
<th>Continuation of clonidine or prasugrel?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGD and colonoscopy</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>– +/- biopsy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EUS without FNA</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Colonic polypectomy ≤ 1 cm</td>
<td>Yes</td>
<td>No*</td>
</tr>
<tr>
<td>Dilution of digestive stenoses</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>EUS-FNA of solid masses</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Digestive stenting</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>ERCP with stent placement or papillary balloon dilation without endoscopic sphincterotomy</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Argon plasma coagulation</td>
<td>Yes</td>
<td>No†</td>
</tr>
<tr>
<td>High risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMR, ESD and ampullary resection</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Endoscopic sphincterotomy</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Endoscopic sphincterotomy + large-balloon papillary dilation</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Colonic polypectomy &gt; 1 cm</td>
<td>Yes</td>
<td>No*</td>
</tr>
<tr>
<td>EUS-FNA of cystic lesions</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Percutaneous endoscopic gastroscopy</td>
<td>Yes</td>
<td>n.a.</td>
</tr>
<tr>
<td>Esophageal variceal band ligation</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

EGD, esophagogastroduodenoscopy; ERCP, endoscopic retrograde cholangiopancreatography; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; EUS, endoscopic ultrasonography; EUS-FNA, endoscopic ultrasonography-guided fine needle aspiration; n.a., not available.

* Bleeding may be prevented by placing a detachable loop ligating device or, if not possible, by submucosal injection of diluted adrenaline. The resection of small polyps (< 1 cm) is probably safe in patients taking clopidogrel (not prasugrel) with such preventive measures; insufficient data are available concerning prophylactic endoclip placement.

† Argon plasma coagulation can be safely used to treat angiodyplasias without withholding thienopyridines.

Table 3 Endoscopic procedures and risk of bleeding.

APA, antiplatelet agent; DES, drug-eluting stent; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; EUS-FNA, endoscopic ultrasonography-guided fine needle aspiration; PEG, percutaneous endoscopic gastrostomy.

* Patients with a low thrombotic risk receive a single antiplatelet agent; those with a high thrombotic risk receive two antiplatelet agents.

† Thienopyridines should be stopped (clopidogrel 5 days and prasugrel 7 days) prior to procedure and aspirin substituted. Thienopyridines will be resumed shortly after the procedure if aspirin is inadequate for long-term prevention.
Endoscopic mucosal resection and submucosal dissection
The risk of bleeding doubles when lesions are removed by endoscopic submucosal dissection (ESD) compared with endoscopic mucosal resection (EMR) (Evidence level 1+). Both techniques have always been performed after withholding APA; a short washout period has been associated with more post-procedure bleeding after gastric ESD (Evidence level 2–). For EMR and ESD, discontinuation of all APA, including aspirin, is recommended provided the patient is not at high risk for a thrombotic event (Recommendation grade B).

Endoscopic biliary and pancreatic sphincterotomy
The risk of post-endoscopic sphincterotomy hemorrhage (PESH) is not increased with aspirin use (Evidence level 2+). The risk of PESH has not been sufficiently assessed when clopidogrel or prasugrel were continued. PESH is significantly less frequent when blended rather than pure-cutting current is used during endoscopic sphincterotomy. Large-balloon papillary dilation after endoscopic sphincterotomy for extraction of difficult biliary stones has been associated with frequent intra-procedural oozing and, less frequently, severe bleeding (Evidence level 2+); no data have been reported with this technique in patients taking APA.

For endoscopic sphincterotomy, it is recommended: (i) to continue aspirin (Recommendation grade C), (ii) to withhold clopidogrel or prasugrel (Recommendation grade D), and (iii) to use blended current (Recommendation grade A). For the extraction of large biliary stones in patients taking aspirin, mechanical lithotripsy is recommended over endoscopic sphincterotomy plus large-balloon dilation (the latter technique should be performed after withholding any APA) (Recommendation grade D).

If APA discontinuation is considered too risky, EPBD using small-caliber (≤10mm) balloons and, for obstructing biliary stones, temporary stent placement without endoscopic sphincterotomy. The respective drawbacks of each of these alternatives include an increased risk of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) and a high morbidity/mortality in the case of long-term biliary stent placement (Evidence level 1+).

Endoscopic ultrasound-guided fine-needle aspiration
Based on limited data, aspirin does not increase the hemorrhagic risk of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) (Evidence level 2+); no data were found for thienopyridines. In the case of pancreatic cystic lesions, EUS-FNA could carry a higher incidence of bleeding compared with other lesions but data are conflicting. After EUS-guided brushing of pancreatic cysts, severe delayed bleeding has been reported in patients receiving anticoagulant therapy, even when withheld before the procedure (Evidence level 2–).

It is recommended that thienopyridines are discontinued before any EUS-FNA and that aspirin be withheld before EUS-FNA of pancreatic cysts in patients with a low risk of thrombotic events. EUS-guided brushing of pancreatic cysts is not advised in patients receiving any APA, even if these are temporarily discontinued (Recommendation grade D). For other EUS-FNAs, aspirin should not be discontinued (Recommendation grade C).

Endoscopic stent placement and dilation of gastrointestinal strictures
No studies have specifically evaluated the bleeding risk associated with endoscopic dilation or stent placement in patients taking APA but the overall bleeding risk associated with these procedures is very low (Evidence level 2+).

For endoscopic dilation of digestive strictures or stent placement, we recommend not to discontinue aspirin (except when large-diameter pneumatic achalasia balloon dilation is performed), but to discontinue clopidogrel or prasugrel (Recommendation grade D).

Percutaneous endoscopic gastrostomy (PEG) placement
There are limited data on the bleeding risk associated with percutaneous endoscopic gastrostomy (PEG) placement in patients taking APA: three recent studies have shown that aspirin does not increase the bleeding risk (Evidence level 2+). We recommend continuing aspirin in patients undergoing PEG placement (Recommendation grade C). In the absence of appropriate studies, no recommendation can be made for patients taking clopidogrel or a combination of aspirin and thienopyridines.

Device-assisted enteroscopy
The bleeding risk of device-assisted enteroscopy (using either single- or double-balloon or spiral techniques) in patients taking APA has not been formally evaluated. We recommend continuing aspirin and considering discontinuation of thienopyridines (Evidence grade D).

Esophageal variceal ligation (EVL)
In the only published small-sized study of prophylactic EVL, the risk of bleeding was similar in patients taking aspirin or not (Evidence level 2–). It is recommended that for EVL aspirin is continued (Recommendation grade C) and thienopyridines are withheld (Recommendation grade D).

Hemostatic treatment using argon plasma coagulation (APC)
There are limited data on the use of argon plasma coagulation (APC) in patients taking aspirin and other APA. In one study, aspirin and clopidogrel were not identified as risk factors for delayed bleeding after APC of mucosal vascular lesions (Evidence level 2+). It is recommended that aspirin or clopidogrel is continued in patients undergoing APC of potentially bleeding lesions (Recommendation grade C). In the absence of appropriate studies, no recommendation can be made for patients taking a combination of aspirin and thienopyridines.
4. Antiplatelet agents

4.1. Pharmacology and clinical use

Low doses of aspirin and thienopyridines (clopidogrel and prasugrel) irreversibly inhibit platelet aggregation. The minimal durations of APA discontinuation that allow for restoration of normal platelet aggregability are 5 days for aspirin/clopidogrel and 7 days for prasugrel. APA management during the periendoscopic period balances the estimated risk of bleeding associated with the intended procedure and the risk of a thrombotic event when APA are withheld. The risks of bleeding associated with the most commonly performed endoscopic procedures are discussed in the following paragraphs. A summary of general and specific recommendations for the management of APA therapy during the periendoscopic period is presented in Table 2 and 3.

Aspirin and thienopyridines (clopidogrel and prasugrel) are the most commonly used APA [6, 7]; they have different mechanisms of action on platelets and are often used in combination:

- Aspirin commonly used at low dosage (75 to 160 mg daily) decreases platelet aggregation by irreversibly inhibiting cyclooxygenase-1, thus blocking the synthesis of thromboxane A2, a potent platelet-activating agent. Although the half-life of aspirin is short, its effect lasts for the lifespan of the platelets.

- Clopidogrel is an inactive pro-drug; following intestinal absorption, it is extensively transformed into an inactive metabolite that requires cytochrome P450-dependent metabolic activation. The active metabolite irreversibly binds to an adenosine diphosphate platelet receptor and, hence, irreversibly inhibits platelet aggregation.

- Prasugrel has the same pharmacologic action as clopidogrel but with more consistent levels of platelet inhibition with less susceptibility to genetic variation and drug–drug interactions [8].

The efficacy of aspirin and clopidogrel largely varies between individuals, depending on the state of platelet activation and genetic factors. No routine hemostatic tests can reliably assess the level of platelet activity in patients taking APA and help to assess the hemorrhagic risk. Platelet counts and coagulation tests are only useful in these patients to search for other potential causes of increased bleeding risks, particularly in the case of bleeding history.

In the near future, ticagrelor, a novel APA chemically distinct from thienopyridines that reversibly inhibits platelets, might simplify the perioperative and periendoscopic management of patients taking APA [9]. Pharmacological studies have shown that prasugrel and ticagrelor have a more potent and reliable antiplatelet effect than clopidogrel and these drugs may therefore present a higher hemorrhagic risk.

In many cases, oral anticoagulants or heparin cannot be used as a substitute for APA. For example, heparin (unfractionated or low-molecular-weight heparin) is not recommended for the prevention of coronary stent thrombosis.

4.2. Discontinuation of antiplatelet agents

As 10% of platelets renew each day and a concentration of 50,000 new platelets per microliter of blood confers normal clotting, it can be calculated that the minimal durations of APA discontinuation that allow for restoration of normal platelet aggregability are 5 days for aspirin/clopidogrel and 7 days for prasugrel (based on the prolonged and more effective action of prasugrel compared with clopidogrel) [8].

Patients who require two APA due to high thrombotic risk should never discontinue aspirin and any consideration regarding the withholding of thienopyridines should first be discussed with a cardiologist. For patients taking clopidogrel alone, aspirin can be substituted during the periendoscopic period for high-risk bleeding procedures. To date, no published data are available concerning the bleeding risk associated with the use of ticagrelor. APA treatment should be resumed no later than 24–48 hours after the procedure but may be delayed on a case-by-case basis to prevent severe bleeding complications [7]. A summary of recommendations is seen in Table 2 and 3.

5. Endoscopic procedures

5.1. Standard diagnostic endoscopy with or without mucosal biopsy

Esophagogastroduodenoscopy (EGD), colonoscopy, push enteroscopy and endoscopic ultrasonography (EUS) without fine-needle aspiration (FNA) present a minimal bleeding risk (Evidence level 2++). Mucosal biopsy sampling at any digestive site is associated with a very low bleeding risk that is not increased in patients taking APA (aspirin or clopidogrel) (Evidence level 2+). Prasugrel is likely to confer a low bleeding risk similar to that of clopidogrel in diagnostic endoscopic procedures (Evidence level 4).

For the diagnostic endoscopic procedures listed above without biopsy sampling, it is recommended to continue all APA treatment (Recommendation grade B). If biopsy sampling is indicated in patients taking single APA therapy of aspirin or clopidogrel, we recommend continuing APA therapy (Recommendation grade C). In patients taking a combination of aspirin and thienopyridines, we recommend continuing dual APA therapy if mucosal biopsies without electrocautery are anticipated (Recommendation grade D). For small-caliber EGD, the transoral rather than the transnasal route should be considered in patients receiving dual APA therapy (Recommendation grade D).

The risk of bleeding associated with diagnostic endoscopy has been assessed in several large studies that included in total thousands of patients [10–13]. These studies have shown that bleeding is very rare after diagnostic endoscopic procedures, including those with mucosal biopsy sampling. No episodes of severe bleeding have been reported. Transnasal esophagogastroduodenoscopy (EGD) may be associated with an increased risk of epistaxis, depending on the diameter of the endoscope [14,15]. However, these studies were not designed to examine bleeding risks in patients taking aspirin or thienopyridines.

Four studies have specifically evaluated the bleeding risk of diagnostic endoscopy with biopsy sampling in patients taking APA [16–19]. In a nonrandomized study of 180 patients, colonic mucosal bleeding time was significantly increased in patients taking APA but without clinical consequences [16]. Another study showed that aspirin did not prolong gastric bleeding time [17]. A retrospective study of 133 patients (including 16 patients taking NSAIDs), in whom multiple (9661) biopsy samples were obtained during 253 endoscopies, found that minor complications occurred in only 13 (5.1%) patients, including 8 episodes of self-limited bleeding [19]. Multivariate analysis showed no increased bleeding risk in patients with recent NSAID use. Neither the type of endoscopic procedure nor the site of biopsy was associated with bleeding.

Two previous national guidelines on APA management for endoscopic procedures recommended continuing aspirin and/or clo-
Post-polypectomy bleeding (PPB) is more frequent with the use of pure-cutting current as compared with blended or coagulation current. (Evidence level 2+). Definite risk factors for PPB include age > 65 years, anticoagulation, cardiovascular disease, polyp size ≥ 1 cm (Evidence level 2++). Aspirin does not increase the risk of PPB, irrespective of polyp size (Evidence level 2++). In patients taking clopidogrel, resection of small polyps (≤ 1 cm) followed by endoclip placement (either routinely or in cases of excessive intraprocedural bleeding) has been reported to be relatively safe; in these patients, the use of clopidogrel alone was not an independent predictor of PPB but the concomitant use of clopidogrel and aspirin/NSAID (nonsteroidal anti-inflammatory drugs) was an independent predictor (Evidence level 2+). Endoscopic interventions that are effective in preventing PPB include placement of a detachable loop ligating device for large pedunculated polyps and submucosal injection of diluted adrenaline for sessile polyps. Efficacy of other measures, including endoclip placement, injection of saline and argon plasma coagulation, has not been definitively demonstrated (Evidence level 1+).

For polypectomy, it is recommended that pure-cutting current is not used (Recommendation grade C). It is also recommended that aspirin is not discontinued irrespective of polyp size (Recommendation grade B), and that thienopyridines are withheld if polyps > 1 cm have to be resected, provided that the patient is not at high risk for thrombotic events (Recommendation grade C). When polyps must be resected in patients who cannot discontinue thienopyridines, preventive measures (preferably detachable loop ligating device for pedunculated polyps, and submucosal injection of diluted adrenaline for sessile polyps) should be readily available (Recommendation grade B). In patients with large polyps who are receiving thienopyridines, biopsy sampling with deferral of polypectomy should be considered (Recommendation grade D).

Only two high-quality studies were identified in which the incidence of post-polypectomy bleeding (PPB) could be calculated: these studies were recent, large, and prospective with a minimum follow-up of 14 days after polypectomy [22, 23]. The overall incidence of PPB was 2.9% (199/6849 patients) and the incidence of severe PPB (defined as requiring blood transfusion, hospitalization, surgery, or resulting in death) was 1.1% (43/3929 patients) [22].

Definite and likely risk factors for PPB are summarized in Table 4. Among polyp-related factors, a large polyp size is the most consistent risk factor. It has been calculated that for every 1-mm increase in polyp diameter, the risk of PPB increases by 9% [23].

Good clinical practices for the resection of large polyps include the use of endoscopic interventions that have been demonstrated to effectively prevent PPB (Table 5). Furthermore, referral to specialized centers should be considered. In a study of 174 patients referred for resection of large or complex polyps (median diameter, 30 mm), delayed PPB occurred in 3.7% of patients [35]. For colonic snare polypectomy, the use of pure-cutting current is not recommended because it increases the incidence of immediate PPB compared with blended or coagulation currents [24, 36]. Blended and coagulation currents are associated with similar incidences of PPB, but PPB tends to develop later (up to 8 days) after polypectomy with coagulation compared with blended current [37].

The influence of aspirin use on PPB has been analyzed in case–control studies including a total of 30,000 patients (Table 6). These studies varied in many aspects, including design, definition of PPB, technique of polypectomy, methods used for selecting controls with no PPB, and discrimination of aspirin from other NSAIDs. Despite these differences, all studies found that the risk of significant PPB was not increased by aspirin use.

The influence of clopidogrel intake on PPB has been analyzed in two retrospective studies including 202 patients taking clopidogrel (associated with aspirin/NSAID use in 27%) undergoing 500 polypectomies (polyp size ≤ 10 mm in 93% of cases) [41, 42]. In 6% of patients, the polypectomy was associated with immediate bleeding which was successfully treated by endoclip placement. Delayed PPB developed in 3% of patients. Of note, endoclips were placed after all polypectomies in one of the two studies and in only 4.2% of patients in the second study. Bleeding developed up to 14 days after polypectomy. In one study there was a control group (1243 patients undergoing polypectomy in the absence of clopidogrel) which allowed identification of independent risk factors for PPB [41]. Risk factors included the concomitant use of clopidogrel and aspirin/NSAID but not the use of clo-

| Table 4 | Risk factors* for hemorrhagic adverse events following colonic polypectomy. |
|-----------------|-----------------|-----------------|
| **Patient-related risk factors** | Adjusted odds ratios (95% confidence interval)† |  |
| **Definite risk factors** | |  |
| − Age > 65 years | 1.37 – 1.69 (range, 1.02 – 2.42) |  |
| − Anticoagulation | 3.71 – 5.2 (range, 1.05 – 13.05) |  |
| − Cardiovascular disease | 2.08 – 2.30 (range, 1.45 – 6.2) |  |
| **Likely risk factors** | |  |
| − Male gender | 1.92 (1.35 – 2.77) |  |
| − Arterial hypertension | 5.60 (1.80 – 17.20) |  |
| − Chronic renal disease | 3.29 (1.84 – 5.87) |  |
| **Polyp-related risk factors** | |  |
| **Definite risk factor** | |  |
| − Size ≥ 1 cm | 2.38 – 4.40 (range, 1.78 – 10.30) |  |
| **Likely risk factor** | |  |
| − Morphology (sessile, laterally spreading tumor) | 1.42 (1.06 – 1.89) |  |
| **Technique-related risk factors** | |  |
| **Likely risk factors** | |  |
| − Use of pure-cutting current | 6.95 (4.42 – 10.04) |  |
| − Inadvertent cold polypectomy | 7.15 (3.13 – 16.36) |  |
| − Endoscopist case volume < 300 colonoscopies/year | 2.32 (1.25 – 4.3) |  |
| − Poor bowel preparation | 1.54 (1.06 – 1.89) |  |

* Risk factors for post-polypectomy bleeding were defined as definite or likely if they were identified by multivariate analysis in a majority or a minority of studies that included these factors in the analysis, respectively [23–27].
† For 95% confidence intervals, the range of values reported in different studies is presented if the risk factor was identified in several studies.
‡ Endoscopist experience was a predictor of post-polypectomy bleeding only if the endoscopist was not a gastroenterologist [36].
In such difficult cases, the endoclip-assisted technique, consisting of mucosal injection and may not be feasible for very large polyps. The disadvantage of detachable loop ligating devices is that their placement requires more expertise than submucosal injection. The advantage of adrenaline was found to be more effective than saline for patients with polyps ≥2 cm (see text for details).

### Table 5

Randomized controlled trials of endoscopic interventions to prevent bleeding after snare resection of large colon polyps in patients taking no antiplatelet agent.

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Patients, n</th>
<th>Methods compared</th>
<th>Polyp size, mm</th>
<th>Bleeding incidence (immediate + delayed)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dobrowolski, 2004 [28]</td>
<td>69</td>
<td>Adrenaline vs. no intervention</td>
<td>&gt; 10</td>
<td>2% vs. 16%</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Lee, 2007 [29]</td>
<td>486</td>
<td>Adrenaline vs. saline injection</td>
<td>&gt; 20</td>
<td>4.9% vs. 10.4%</td>
<td>0.03*</td>
</tr>
<tr>
<td>Ishii, 1996 [30]</td>
<td>89</td>
<td>Detachable loop ligating device vs. no intervention</td>
<td>&gt; 10</td>
<td>0% vs. 12%</td>
<td>0.02*</td>
</tr>
<tr>
<td>Di Giorgio, 2004 [31]</td>
<td>488</td>
<td>Detachable loop ligating device vs. adrenaline vs. no intervention</td>
<td>22.1 vs. 24.7 vs. 21.5</td>
<td>1.8% vs. 3.1% vs. 7.9%</td>
<td>n.s.†</td>
</tr>
<tr>
<td>Kouklakis, 2009 [32]</td>
<td>64</td>
<td>Adrenaline vs. detachable loop ligation device + clip</td>
<td>&gt; 20</td>
<td>12.5% vs. 3.1%</td>
<td>0.02</td>
</tr>
<tr>
<td>Paspatis, 2006 [33]</td>
<td>159</td>
<td>Adrenaline vs. adrenaline + detachable loop ligating device</td>
<td>&gt; 20</td>
<td>10.6% vs. 2.3%</td>
<td>0.02</td>
</tr>
<tr>
<td>Lee, 2009 [34]</td>
<td>475</td>
<td>Argon plasma coagulation vs. no intervention</td>
<td>9.8 vs. 9.5</td>
<td>2.5% vs. 4.3%</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

n.s., not significant.  
† Statistically significant in subgroup analysis of polyps ≥2 cm (see text for details).

### Table 6

Case–control studies evaluating the risk of hemorrhagic adverse events following colonic polypectomy relative to aspirin intake.

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Study design</th>
<th>Number of patients</th>
<th>Incidence of PPB in the whole study population</th>
<th>Patients taking aspirin</th>
<th>Controls (no PPB)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shiffman, 1994 [38]</td>
<td>Prospective 464</td>
<td>Any 6.5%</td>
<td>73% (22/30)</td>
<td>47% (206/434)</td>
<td>0.009</td>
<td></td>
</tr>
<tr>
<td>Yousfi, 2004 [39]</td>
<td>Retrospective 20636</td>
<td>Any 0.5%</td>
<td>100% (2/2)</td>
<td>0% (0/2)</td>
<td>0.73</td>
<td></td>
</tr>
<tr>
<td>Hui, 2004 [40]</td>
<td>Retrospective 1657</td>
<td>Any 2.2%</td>
<td>40% (32/81)</td>
<td>33% (27/81) †</td>
<td>0.36</td>
<td></td>
</tr>
<tr>
<td>Heldwein, 2005 [22]</td>
<td>Prospective 2257</td>
<td>Any 8.6%</td>
<td>14% (5/37)</td>
<td>8% (122/1620)</td>
<td>0.62</td>
<td></td>
</tr>
<tr>
<td>Sawhney, 2008 [23]</td>
<td>Retrospective 4592</td>
<td>Delayed 0.9%</td>
<td>41% (17/41)</td>
<td>39% (51/132) †</td>
<td>0.80</td>
<td></td>
</tr>
</tbody>
</table>

n.d., no data; n.s., not significant; PPB, post-polypectomy bleeding.

* Defined as blood loss either warranting emergency consultation [38], or leading to shock, blood transfusion, hospitalization, or surgery, or recurrent bleeding after endoscopic hemostasis [22].
† Controls were selected among study patients who did not develop PPB, either randomly [23], or after matching for age, gender, and cardiovascular morbidity [39].

pidogrel alone as well as the number of polyps resected. Because polyps are found at screening colonoscopy in one-third of average-risk patients, the authors concluded that it is unnecessary to stop clopidogrel therapy for screening colonoscopy in average-risk patients provided that endoclips are readily available.

Various endoscopic interventions have been used to prevent delayed PPB in patients not taking APA (Table 5). Hence, the recommendations presented here for PPB prophylaxis are based on evidence extrapolated from these studies. Submucosal injection of diluted adrenaline was found to be more effective than saline or no intervention in the three RCTs that compared these modalities (in one RCT, the difference was statistically significant only for patients with polyps ≥2 cm) [31]. In the case of large pedunculated polyps, the placement of a detachable loop ligating device and injection of adrenaline were similarly effective in only one of three RCTs [31]. The disadvantage of detachable loop ligating devices is that their placement requires more expertise than submucosal injection and may not be feasible for very large polyps. In such difficult cases, the endoclip-assisted technique, consisting of clip placement on the polyp pedicle followed by polypectomy using a snare or a needle-knife, has been shown to be as safe and effective as detachable loop ligation device-assisted polypectomy in a small case–control study [43]. There is no evidence that argon plasma coagulation is effective in reducing the risk of PPB [34]. An RCT of prophylactic endoclip placement versus no treatment was not included in our review as patients with large polyps were excluded, resulting in insufficient statistical power to demonstrate efficacy of a prophylactic intervention [44]. A retrospective study that included 123 patients receiving anticoagulants reported an acceptable PPB rate (2.5%) after resection of 225 polyps (mean and maximum sizes, 5 and 15 mm, respectively) followed in all cases by prophylactic endoclip placement [45].

#### 5.3. Endoscopic mucosal resection (EMR) and submucosal dissection (ESD)

The risk of bleeding doubles when lesions are removed by endoscopic submucosal dissection (ESD) compared with endoscopic mucosal resection (EMR) (Evidence level 1+). Both techniques have...
always been performed after withholding APA; a short washout after gastric ESD (Evidence level 2–). The risk of PESH has not been sufficiently assessed when clopidogrel or prasugrel were continued. PESH is significantly less frequent when blended rather than pure-cutting current is used during endoscopic sphincterotomy. Large-balloon papillary dilation after endoscopic sphincterotomy for extraction of difficult biliary stones has been associated with frequent intraprocedural oozing and, less frequently, severe bleeding (Evidence level 2+); no data have been reported with this technique in patients taking APA.

Alternatives to endoscopic sphincterotomy that eliminate the risk of bleeding include endoscopic papillary balloon dilation (EPBD) using small-caliber (<10mm) balloons and, for obstructing biliary stones, temporary stent placement without endoscopic sphincterotomy. The respective drawbacks of each of these alternatives include an increased risk of PEP and a high morbidity/mortality in the case of long-term biliary stent placement (Evidence level 1+).

For endoscopic sphincterotomy, it is recommended: (i) to continue aspirin (Recommendation grade C), (ii) to withhold clopidogrel or prasugrel (Recommendation grade D), and (iii) to use blended current (Recommendation grade A). For the extraction of large biliary stones in patients taking aspirin, mechanical lithotripsy is recommended over endoscopic sphincterotomy plus large-balloon dilation (the latter technique should be performed after withholding any APA) (Recommendation grade D).

If APA discontinuation is considered too risky, EPBD using small-caliber balloons or temporary biliary stent placement should be considered as an alternative. If EPBD is performed in young patients, the placement of a prophylactic pancreatic stent should be considered (if the endoscopist is not proficient in this technique, biliary stent placement is recommended rather than EPBD). After biliary stent placement, the patient and referring physicians should be warned that when used as a long-term measure, stent placement is associated with a high risk of cholangitis (Recommendation grade B).

Clinically significant PESH complicates 2% of endoscopic sphincterotomies [66]. Recognized risk factors for PESH include cholangitis, coagulation disorders, institution of anticoagulation within 3 days of endoscopic sphincterotomy, low endoscopist case volume of endoscopic sphincterotomies, and bleeding observed during the procedure [67]. For endoscopic sphincterotomy, blended current is recommended as it reduces the incidence of PESH compared with pure-cutting current without significantly increasing the risk of PEP [36, 68].

Three studies that assessed PESH in patients taking APA were identified. In the only prospective study [66], PESH occurred in 2% of patients, regardless of the use of aspirin or NSAIDs in the 3 days preceding the procedure (PESH and APA, 6/288 vs. PESH and no APA, 42/2299; P = 0.99). In a retrospective case–control study, similar proportions of patients taking APA were found among 40 patients with PESH compared with 86 controls without PESH (13% aspirin and 3% clopidogrel vs. 17% aspirin and 4% NSAIDs in cases vs. controls, respectively) [69]. In another retrospective case-control study [70], PESH occurred slightly less frequently in 564 controls who had not taken aspirin compared with 240 patients taking aspirin (regardless of whether they had continued or stopped aspirin 1 week prior to endoscopic sphincterotomy).

In that study, PESH was more strongly associated with co-morbid illness than with aspirin therapy (P < 0.001 and P = 0.04, respectively). No adequately powered study was identified that assessed the risk of PESH in patients taking thienopyridines. For the removal of large or difficult common bile duct stones, a technique that consists of endoscopic sphincterotomy followed by dilation using large-diameter (12–20 mm) balloons is increasingly used with high successful stone clearance rates [71–74]. However, no data are available for this technique in patients taking APA. In a retrospective series, intraprocedural oozing and clinically significant bleeding were frequently observed (32% and 7%, respectively) [75]. Moreover, the only RCT that compared endoscopic sphincterotomy alone with endoscopic sphincterotomy combined with large-balloon dilation found no differences in rates of successful stone clearance, need for mechanical lithotripsy, or complications [76].

Compared with endoscopic sphincterotomy, EPBD is an alternative that eliminates the risk of significant hemorrhage, but is less effective for the removal of large biliary stones and carries a high-
er risk of PEP [77, 78]. Concerns were raised about the risk of severe, life-threatening, PEP in young patients after EPBD, based upon the results of a multicenter US RCT. This trial showed higher rates of severe morbidity following EPBD compared with endoscopic sphincterotomy (P = 0.004), including severe PEP (P = 0.01) [79]. However, this trial was performed before the use of pancreatic stents for prophylaxis of PEP. Therefore, placement of a prophylactic pancreatic stent should be considered in patients undergoing EPBD, if the endoscopist is proficient in this technique [80, 81].

Insertion of a nasobiliary drain or biliary stent without endoscopic sphincterotomy is another therapeutic option to avoid endoscopic sphincterotomy-associated bleeding. Biliary endoscopic sphincterotomy is not necessary for inserting single plastic or metal biliary stents [82]. Stent insertion allows biliary drainage in cases of acute supplicative cholangitis [83]. It has also been reported to partially or completely dissolve biliary stones in > 50% of cases, facilitating subsequent extraction [84–87]. It should be considered as a bridge towards more definitive therapy, as complications (including death in up to 6.7–16% of cases) of long-term stent placement in this setting are frequent during long follow-up [84, 88].

5.5. Endoscopic ultrasound-guided fine-needle aspiration

Based on limited data, aspirin does not increase the hemorrhagic risk of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) (Evidence level 2+); no data were found for thienopyridines. In the case of pancreatic cystic lesions, EUS-FNA could carry a higher incidence of bleeding compared with other lesions but data are conflicting. After EUS-guided brushing of pancreatic cysts, severe delayed bleeding has been reported in patients receiving anticoagulant therapy, even when withheld before the procedure (Evidence level 2–).

It is recommended that thienopyridines are discontinued before any EUS-FNA and that aspirin be withheld before EUS-FNA of pancreatic cysts in patients with a low risk of thrombotic events. EUS-guided brushing of pancreatic cysts is not advised in patients receiving any APA, even if these are temporarily discontinued (Recommendation grade D). For other EUS-FNAs, aspirin should not be discontinued (Recommendation grade C).

Prospective studies have shown that bleeding following EUS-FNA is rare and occurs in <1% of unselected patients [89–94]. One prospective study assessed the risk of bleeding complicating EUS-FNA in patients taking aspirin/NSAIDs [95]. In this study, 241 lesions were sampled, including solid tumors, cysts and ascites with a mean of approximately 2.5 passes using a 19G or 22G needle. There was no significant difference in bleeding between those taking aspirin/NSAIDs (0 of 26 patients) compared with controls (7 of 190 patients). No difference was detected between groups in terms of cellular yield. There are no studies identified that assessed bleeding after EUS-FNA in patients taking thienopyridines.

The risk of bleeding may be greater when EUS-FNA is performed for pancreatic cystic lesions. In two prospective cohort studies bleeding occurred in 5.5% of 72 patients, and one of the patients required surgery [94,96]. However, in a prospective multicenter cohort study that included 341 patients no bleeding occurred [97]. In four prospective studies of EUS-guided brushing of pancreatic cysts, severe bleeding occurred in 1.5% of 130 patients, including one that was fatal [98–101]. Bleeding was delayed (7–16 days post-procedurally) and occurred in patients who had anticoagulant therapy discontinued at the time of brushing.

5.6. Endoscopic stent placement and dilation of gastrointestinal strictures

No studies have specifically evaluated the bleeding risk associated with endoscopic dilation or stent placement in patients taking APA but the overall bleeding risk associated with these procedures is very low (Evidence level 2+).

For endoscopic dilation of digestive strictures or stent placement, we recommend not to discontinue aspirin (except when large-diameter pneumatic achalasia balloon dilation is performed), but to discontinue clopidogrel or prasugrel (Recommendation grade D). No studies could be identified that have specifically assessed the bleeding risk in patients on APA who have undergone dilation or stent insertion in the esophagus, small bowel and colon. The bleeding risk associated with these procedures is as follows below.

Stenosis dilation

In a study of 1043 dilations of benign esophageal strictures with bougie or olive dilators, no cases of significant bleeding were recorded [102]. The same authors published a series of 2750 dilations of benign esophageal strictures using Savary bougies and again no major bleeding was recorded [103]. In a study of 472 esophageal balloon dilations, no bleeding was reported [104]. In a series of 98 balloon dilations of anastomotic strictures of the cervical esophagus no bleeding complications occurred [105]. However, none of these studies was primarily designed to evaluate the risk of bleeding associated with dilation. A study of the complications arising from 504 esophageal dilations in 237 patients with achalasia revealed 4 (1.7%) asymptomatic hematomas, but no clinical bleeding [106]. In addition, there were 7 (3%) perforations.

Regarding colonic or small bowel dilations, no cases of bleeding were reported in 7 case series of ileal or colonic dilation [107–113] of strictures caused by Crohn’s disease and surgical anastomoses. Two additional case series reported a small number of bleeding complications associated with dilation of ileal (1/20, 5%) and colonic strictures (1/38, 2.6%) [114,115]. Another study reported no bleeding complications after dilation of 68-malignant and 26 benign anastomotic strictures [116]. Again, none of the above studies was primarily designed to evaluate the risk of bleeding associated with stricture dilation.

Stent insertion

No studies have specifically evaluated the bleeding risk associated with endoscopic stent placement in the esophagus, duodenum or colon in patients taking APA.

In the preparation of this Guideline a literature search on self-expandable metal colonic stent placement was restricted to studies published after 1995. In a review published in 2002 which included 58 reports of colonic stent placement published from 1990 to 2000, consisting of case reports (n = 38), single case reports (n = 11), and reviews of the literature or letters (n = 9), a total of 27 bleeding complications were reported in 598 patients [117]. Of these, 24 episodes were mild and self-limited. Only 3 patients (0.5%) suffered from severe bleeding requiring blood transfusions. A second systematic review of the literature published in 2006 collated 27 studies published between 2000 and 2006 and included 325 patients with malignant colonic obstruction [118]. There were no reported cases of gastrointestinal bleeding. A third
systematic review of the literature selected 54 publications, none of which was randomized [119]. These were mainly case studies, editorials and literature reviews, involving in total 1192 patients (791 palliative and 401 preoperative). No cases of gastrointestinal bleeding were recorded. In a retrospective study of 102 stent placements no bleeding occurred, but there were 4 (4%) perforations [120]. A multicenter prospective study of 44 stent placements revealed one case of hematoma that resolved spontaneously and no perforations [121].

In a systematic review of the literature of stents placed in the duodenum for malignant obstruction, 32 case series, including 10 prospective studies were identified [122]. Among 606 patients treated, 3 bleeding episodes (0.5%) were reported. In a national survey published in 1997 there was a bleeding complication rate of 0.5% (2/434) with self-expandable esophageal stents [123]. An international multicenter prospective cohort study conducted between 1996 and 2003 assessed the efficacy and safety of enteral stents [124]. A total of 188 enteral stents were placed in 176 patients (88 pancreas cancers, 20 stomach cancers, 15 cholangiocarcinomas, 33 metastases, 8 ampullary adenocarcinoma, and 16 miscellaneous). Two patients (1%) developed gastrointestinal bleeding; no information was given on the severity and management of bleeding.

American guidelines on the management of APA for patients undergoing endoscopic procedures classified the insertion of gastrointestinal stents as procedures with low hemorrhagic risk, in the same category as colonoscopy or EGD +/- biopsy [20]. The authors of these guidelines suggested that it is possible to insert gastrointestinal stents in patients taking aspirin and other APA.

5.10. Hemostatic treatment using argon plasma coagulation (APC)
There are limited data on the use of argon plasma coagulation (APC) in patients taking aspirin and other APA. A recent retrospective single-center cohort case-control study of 990 patients, including 63 patients on aspirin and 50 patients on clopidogrel did not reveal any increase in bleeding in patients taking aspirin or clopidogrel [127].

5.11. Hemostatic treatment using argon plasma coagulation (APC) has not been formally evaluated. We recommend continuing aspirin and considering discontinuation of thienopyridines (Evidence grade D).

During the last 10 years, improvements in enteroscopic techniques have rendered push enteroscopy obsolete except for evaluation and treatment of the proximal jejunum. A systematic review of the literature regarding device-assisted enteroscopy using double- or single-balloon techniques and spiral enteroscopy failed to reveal any studies which assessed the risk of bleeding in patients taking APA. The overall bleeding risk of enteroscopy has been estimated at 0.2% [128]. In a study of enteroscopy and polypectomy, bleeding occurred in 3.3% of patients [129]. Spiral enteroscopy is a newer technique that may cause mucosal trauma but has not been associated with a specific risk of bleeding [130].

5.9. Esophageal variceal ligation (EVL)
In the only published small-sized study of prophylactic EVL, the risk of bleeding was similar in patients taking aspirin or not (Evidence level 2–). It is recommended that for EVL aspirin is continued (Recommendation grade C) and thienopyridines are withheld (Recommendation grade D).

The risk of delayed bleeding following EVL (2.4%–5.7%) and sclerotherapy (4%–25%) is high [131, 132]. Five RCTs show that the risk of delayed bleeding is lower with band ligation than sclerotherapy [133–137]. One recent case-control study examined the risk of bleeding following EVL in a subgroup of patients taking aspirin [138]. Of 605 cirrhotic patients undergoing 837 endoscopies for emergent or prophylactic EVL, only 8 were taking aspirin. Multivariate analysis found no increased risk of bleeding with aspirin therapy.

5.8. Device-assisted enteroscopy
The bleeding risk of device-assisted enteroscopy (using either single- or double-balloon or spiral techniques) in patients taking APA

Institutions
1 Department of Digestive Endoscopy, Hôpital Saint Joseph, Marseille, France
2 Endoscopy and Bowel Cancer Screening, New Cross Hospital, Wolverhampton, UK
3 Department of Gastroenterology and Endoscopy, Hôpital universitaire l’Arche, Nice, France
4 Service de Pathologie Digestive, Hôpital Saint Philibert, Lomme, France
5 Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
6 Department of Gastroenterology and Endoscopy, Hôpital de la Timone, Marseille, France

Shiffman ML, Farrel MT, Yee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDs. Gastrointest Endosc 1994; 40: 458–462


Yousfi M, Gostout CJ, Baron TH et al. Colonoscopy and antiplatelet agents... Endoscopy 2011; 43: 445–458

Boustière C et al. ESGE Guideline: Endoscopy and antiplatelet agents... Endoscopy 2011; 43: 445–458

Guidelines

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

Boustière C et al. ESGE Guideline: Endoscopy and antiplatelet agents... Endoscopy 2011; 43: 445–458


29 Ramirez M, Banner K, Nannelegari V et al. Does aspirin increase the risk of bleeding for percutaneous endoscopic gastrostomy procedure? Gastrointest Endosc 2006; 63: AB113


45 Pescatori M, Rubin P, Fissetta M, D’Eudia E et al. Highdose aspirin or clopidogrel before or after percutaneous endoscopic gastrostomy is not associated with postprocedural bleeding. Gastrointest Endosc 2010; 71: AB114


48 Buscatella JM, Dunbar KB, Okolo PM et al. The spiral enteroscopy training initiative: results of a prospective study evaluating the Discovery SB overtube device during small bowel enteroscopy (with video). Endoscopy 2008; 40: 194 – 199


**Supporting information**

The following material is available online

**online content including Appendix e1 – e3 viewable at:**

www.thieme-connect.de/ejournals/abstract/endoscopy/

DOI 10.1016/j.dld.2010.07.009